Drug Trial Radar · NCT06306300
Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30,000
Planned (sponsor's estimate)
Start
Jul 4, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Oswaldo Cruz FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Up to 650,000 people in Brazil are living with chronic hepatitis c virus (HCV) infection. Hepatitis C is a silent disease, and up to 20% of cases can progress to liver cirrhosis and its complications. Rapid tests for diagnosis of HCV infection and non-invasive methods for detecting liver cirrhosis are available in the Brazilian Public Health System. Additionally, safe and highly effective drugs (direct-acting antivirals, DAAs) have been delivered for free for hepatitis C treatment by the Brazilian Unified Health System (Sistema Único de Saúde, SUS) since 2015. Sustained virological response (SVR) rates with DAAs in studies conducted in Brazil and Latin America were higher than 90%. Despite the availability of rapid tests for early diagnosis and effective drugs, the HCV continuum of care remains deficient in Brazil. It is estimated that only 10% of individuals known to have hepatitis C achieve HCV cure (SVR). This is explained by multiple barriers from diagnosis to treatment access, such as low rates of population screening (HCVST are not available in Brazil) and few available slots in tertiary centers for hepatitis C treatment by specialists. International studies have described that SVR rates by simplified hepatitis C treatment performed by non-specialists in the Primary Care System were similar to those treated in tertiary centers by specialists (standard-of-care). However, the optimal strategy for managing hepatitis C within the Brazilian-SUS remains unclear.This project aims to evaluate the improve of the HCV continuum of care by a implementation of a test-and-treat strategy in the Primary Care System in Brazil. The project consists of two parallel studies (and a sub-study). The project consists of two parallel studies (and a sub-study). Study I is a population-based cross-sectional screening study using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit. The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (participants included in Study I). Study II is a phase IV open-label randomized clinical trial to evaluate the non-inferiority of simplified and decentralized hepatitis C treatment ("Simplified-and-Decentralized (SD) HCV treatment"; experimental arm) compared to specialist reference treatment ("Standard-of-Care (SC) HCV treatment"; control arm) within the SUS.
Conditions
- Hepatitis C
Interventions
Specialist - Epclusa 400Mg-100Mg TabletDrug
HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.
Non- specialist - Epclusa 400Mg-100Mg TabletDrug
HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST)Diagnostic test
HCV Self-Testing kit (oral fluid or blood-based) for HCV testing
HCV Rapid Testing kitDiagnostic test
Standard-of-care: HCV Rapid Test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of HCV infectionTime frame: 1 month
- The effectiveness of the HCV treatment with test results.Time frame: 1 month
- Usability of the result of a self-test HCVTime frame: 1 month
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hugo Perazzo
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Evandro Chagas National Institute of Infectious Diseases
Rio de Janeiro, Rio de Janeiro/RJ, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.